BAIN CAPITAL INVESTORS LLC
BAIN CAPITAL INVESTORS LLC's purchase track record
BAIN CAPITAL INVESTORS LLC has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/20/2026 | KLRA | $134.38M | -27.2% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Evercore Lowers Bobs Discount Furniture Price Target to $18. Evercore ISI Group kept its outperform rating for Bobs Discount Furniture but cut its price target to $18. The new target sits above the current support level of $15.43 and below the 52‑week high of $23.49. The rating suggests analysts remain positive while adjusting expectations for the stock’s upside.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Coherent seeks AI edge via TSX listing amid chip stock declines. Coherent is exploring how its AI capacity buildout and a TSX CDR listing could help redefine its competitive edge. This comes as chip stocks face broader market pressure, tumbling on worries about AI investments. The company's strategic moves are being watched during a challenging period for the sector.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Waystar Holding Shows Technical Breakout Setup. ChartMill reports that Waystar Holding has formed a high-quality technical breakout setup. This observation aligns with the stock's current RSI of 62.6, suggesting momentum is present. The company trades at a trailing P/E of 37.7, with an average analyst target of $33.77.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SGRY Volumes Soften as Analysts Debate Valuation. Surgery Partners is experiencing lower trading volumes while analysts continue to debate its value. Recent reports note a significant five-year decline, yet some estimates suggest the stock is still below fair value. The company remains a point of interest within the Russell 2000, with mixed views on its competitive position and future challenges.
Transaction History
| KLRA | ▼ Sell | Other | 17,857,143 | — | 4/20/2026 | View on chart |
| KLRA | ▲ Buy | Open Market | 8,398,438 | $134.4M | 4/20/2026 | View on chart |
| BOBS | ▼ Sell | Open Market | 2,917,500 | $46.5M | 2/13/2026 | View on chart |
| COHR | ▼ Sell | Other | 254,252 | — | 11/10/2025 | View on chart |
| COHR | ▼ Sell | Other | 7,754,252 | — | 11/7/2025 | View on chart |
| COHR | ▼ Sell | Open Market | 7,500,000 | $1075.3M | 11/7/2025 | View on chart |
| WAY | ▼ Sell | Open Market | 4,295,139 | $168.4M | 9/12/2025 | View on chart |
| WAY | ▼ Sell | Other | 516,371 | — | 9/12/2025 | View on chart |
| WAY | ▼ Sell | Open Market | 451,837 | $16.9M | 5/20/2025 | View on chart |
| WAY | ▼ Sell | Open Market | 3,012,253 | $112.6M | 5/16/2025 | View on chart |
| WAY | ▼ Sell | Other | 235,397 | — | 5/16/2025 | View on chart |
| WAY | ▼ Sell | Other | 573,192 | — | 2/24/2025 | View on chart |
| WAY | ▼ Sell | Open Market | 5,652,689 | $218.2M | 2/24/2025 | View on chart |
| WAY | ▼ Sell | Other | 23,936,936 | — | 12/12/2024 | View on chart |
| WAY | ▼ Sell | Other | 23,936,936 | — | 12/12/2024 | View on chart |
| SGRY | ▼ Sell | Open Market | 7,826,870 | $261.7M | 12/19/2023 | View on chart |
| SGRY | ▼ Sell | Other | 474,407 | $0 | 12/19/2023 | View on chart |
| SGRY | ▲ Buy | Grant | 9,183,673 | $225.0M | 11/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Kailera Therapeutics faces scrutiny on weight loss differentiation
Recent analysis highlights the need for Kailera to clearly differentiate its weight loss drug from existing GLP-1 competitors. The stock is currently trading near its support level, reflecting cautious sentiment as investors await concrete progress on the company's obesity treatment pipeline.
Kailera Therapeutics faces scrutiny on weight loss differentiation. Recent analysis highlights the need for Kailera to clearly differentiate its weight loss drug from existing GLP-1 competitors. The stock is currently trading near its support level, reflecting cautious sentiment as investors await concrete progress on the company's obesity treatment pipeline.